Mounjaro prescriptions rose 18-fold in 10 months, and Rep. Seo Young-seok says no alerts fire for multi-month supplies or combined use with appetite suppressants.
Recap by typeshit. Full story at Korea Biomedical Review.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
New EASD analyses, not yet peer reviewed, found about 13 to 14% weight loss at the 36 mg dose and an indirect edge over high-dose oral semaglutide in diabetes.
Partnership for Safe Medicines also notes Eli Lilly suing five more retatrutide sellers and FDA staff concerns over a plan to let compounders dispense unapproved peptides.
Loading…